Bioavailability of a new, long-acting (LA) pharmaceutical preparation for administering doxycycline as in-feed medication to broiler chickens was compared to the standard in-feed administration of doxycycline. A commercial poultry house harboring Ross-308 broiler chickens, weighing 450 g, was divided into 7 sections as follows: doxy-FOLA group (n = 6,000 chickens divided into 3 replicates) medicated with 10% doxycyline, long-acting pellets at a dose of 400 g of doxycycline HCl/ton of food, resulting in a calculated dose of 48 mg/kg for 5 d; doxy-ref group (n = 6,000, divided into 3 replicates) medicated as for doxy-FOLA, but using a 20% commercial preparation of doxycycline. A third group of 300 broiler chickens (divided into 3 replicates), received a single IV dose of 48 mg/kg from a 2.4% solution of doxycycline HCl under ketamine anesthesia. Blood samples were obtained at designated times, serum was harvested, and doxycycline concentrations determined by high-performance liquid chromatography (HPLC). Bioavailability values were 156% and 227% on d 1 and 5 for doxy-FOLA and . Based on 3 levels of bacterial sensitivity of E. coli derived from a small survey carried out (i.e., 1.0, 2.0, and 4.0 μg/mL) and considering pharmacokinetic/pharmacodynamic (PK/PD) ratios required for this time-dependent antibacterial drug, it is possible to postulate that doxy-FOLA outstrips the reference preparation maintaining higher and more prolonged serum concentrations of doxycycline and consequently complying better with PK/PD ratios regarded as optimal for this drug. The advantages of using doxy-FOLA in poultry medicine include a more comprehensive use of the active principle, which in turn should have a better impact on bacterial diseases. Yet, a longer withdrawal time is anticipated based on an almost 4-fold increment in the MRT value.
INTRODUCTION
Aviculture is a highly technified industry that often uses antimicrobial drugs to remain economically viable. Yet the use of these antimicrobials can be optimized, not only through rationalization of their prescription, but also by optimizing pharmaceutical design of antibacterial drugs (Sumano et al., 2000) . Inadequacy of pharmaceutical design for antibacterial drugs intended for the poultry industry has seldom been stressed in the formal literature. Yet, it has been pointed out that there is room for improvement, in particular if optimal use of antibacterial drugs is intended (Sumano et al., 2000; Vermeulen et al., 2002; Sumano and Gutiérrez, 2009) . Given the rapid transit time of food material through the GI tract and the limited surface area for drug absorption in poultry at the duodenal loop (Golian and Maurice, 1992; Rougière and Carré, 2010) , a rational pharmaceutical design of antimicrobial drugs regarded as time-dependent must be directed towards optimizing bioavailability and extending the time-contact of the drug with its absorption sites. One way to achieve this is through gastro-retentive pharmaceutical forms that release the antibacterial drug into the duodenal loop with zero-order kinetics. Consequently, this should allow better duodenal absorption of drugs and reduce the amount of antibacterial drug that is shed through feces.
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With such a design, therapeutic efficacy could be optimized through better compliance with the pharmacokinetic/pharmacodynamic (PK/PD) ratios of such antibacterial drugs (Vermeulen et al., 2002; Sumano and Gutiérrez, 2009) .
Doxycycline is often used to treat avian infectious diseases such as colibacillosis, salmonellosis, staphylococcosis, mycoplasmosis, and chlamydiosis (George et al., 1977; Jakoby, 1979; Goren et al., 1988; Dorrestein et al., 1990) . In many countries, powdered doxycycline HCl for administration in drinking water is available (European Commission, 2011 ) and a calculated dose of 20 mg/kg/day has been approved. Lately, it has been pointed out that clinical efficacy of doxycycline may be explained, in terms of PK/PD ratios, as a time-dependent antibacterial drug. That is, at serum concentrations equal or slightly above the minimum inhibitory concentration (MIC) level, doxycycline inhibits sensitive microorganisms in a time-dependent fashion. Hence, serum concentrations of doxycycline should be at or above MIC values for as long as possible between drug administration intervals (T ≥ MIC) (Cunha et al., 2000) . It has also been pointed out that the ratio of area under the serum concentration vs time curve (AUC 0-24 ) divided by the MIC value of the given pathogen (AUC 0-24 /MIC), may be even better predictor of clinical efficacy than the value of T ≥ MIC (Papich, 2014). However, specific values for AUC 0-24 /MIC have not been yet defined in chickens (McKellar, 2002; Toutain and Lees, 2004; Papich, 2014) . For humans, AUC 0-24 /MIC ratio vs. E. coli has been set at ≥20 (Cunha et al., 2000; Agwuh and MacGowan, 2006) .
Pharmacokinetics of doxycycline in chickens has already been defined (Anadón et al., 1994) . After oral administration (20 mg/kg), the drug is rapidly, but only partially absorbed, with an average bioavailability (F) of 41%. This rather low F of doxycycline may be explained in terms of a reduced surface area for absorption at the duodenum (Saivin and Houin, 1988) , combined with a transit time of 1 to 2 h in the duodenal loop in chickens (Golian and Maurice, 1992; Rougière and Carré, 2010) . In bioequivalence studies of doxycycline in chickens, it has been found that after a dose of 20 mg/kg administered as a bolus solution, serum concentrations ranged from 0.65 to 0.7 μg/mL, and from 0.25 to 0.35 μg/mL, 12 or 24 h later, respectively (Soliman et al., 2015) . Cunha et al. (2000) reported MIC values 1 μg/mL vs sensitive strains of E. coli, and 2 -4 μg/mL for median to low sensitive strains. If the referred serum concentrations are considered, then doxycycline would be either marginally effective or useless to treat infections caused by E. coli. This example is particularly important, considering that the post-antibiotic effect of doxycycline has been defined as concentration dependent and varies between 2.1 and 4.2 h in humans (Cunha et al., 1982) . While a sustained-release or long-acting (LA) oral pharmaceutical preparation of doxycycline seems redundant for dogs, cats, and humans, based on the fact that elimination half-life (T 1 2 β) allows a 24-h dosing interval (DI) (Cunha et al., 1982; Cunha et al., 2000; Agwuh and MacGowan, 2006 ), it appears reasonable to postulate that administering doxycycline to chickens based on a LA formulation may optimize bioavailability of the drug and achieve better compliance with desired PK/PD ratios (T ≥ MIC and AUC 0-24 /MIC). Hence, a pharmacokinetic study was carried out in a commercial broiler house to evaluate a LA dosage form of doxycycline, prepared as small colored pellets (Patent No. MX/a/2012/013222 and PCT/MX2013/000137, Universidad Nacional Autónoma de México [UNAM]), taking a standard commercial preparation of doxycycline as reference.
MATERIAL AND METHODS
Study design and animal handling complied with Mexican regulations for use of experimental animals, as laid out by UNAM and Mexican prescripts in NOM-062-ZOO-1999. This trial was carried out in a commercial farm San Miguel (Di-Pollo S.A. de C.V., Mexico) at Cocula, Jalisco in the central part of Mexico. In all, 12,300 15-day-old Ross-308 broiler chickens, weighing approximately 450 g with a daily gain of 60 g, were distributed by simple randomization within a single chicken house, which was divided into 7 areas by wire mesh as follows: (1) an experimental doxycycline-treated group designated as doxy-FOLA, wherein FOLA stands for bioavailability (F), optimum (O), and long-acting preparation (LA), with 3 replicates (n = 2,000 chickens/replicate) that was in-feed medicated with 10% doxycycline, prepared as orange to yellow color pellets, at a dose of 400 g of doxycycline HCl/ton of food (see preparation of FOLA below); (2) a doxycycline-treated group designated as the doxy-ref group (3 replicates with 2,000 broiler chickens in each replicate) that was in-feed medicated with 20% doxycycline from the commercial preparation Doxifarm R (NF-Feed Products S.A. de C.V., Mexico); and (3) a doxy-IV group (divided into 3 replicates) treated with an intravenous dose of doxycycline, that included 150 males and 150 female broiler chickens. The first group, doxy-FOLA, was given a food consumption of approximately 60 g/day, an individual dose of 48 mg/kg was calculated. Medicated food was given for 5 d and it was made available for chickens at 5 am. The second group, doxy-ref, was also medicated at a dose of 400 g of doxycycline HCl/ton of food, as in doxy-FOLA group. In the third group, doxy-IV, all chickens received a single IV dose of 48 mg/kg (24 mg/chicken = 1 mL), from a 2.4% solution of freshly diluted doxycycline, using pharmaceutical-grade injectable water and by means of 25-gauge butterfly pediatric catheter 20 mm long, inserted in the jugular vein. This procedure was carried out under anesthesia with a single IM dose of 40 mg/kg of ketamine (Anesket R , PiSA Agropecuaria, Mexico City). Doxy-FOLA pellets were manufactured by NF-Feed Products S.A. de C.V., Mexico, based on Patent No.MX/a/2012/013222 and PCT/MX2013/000137 (UNAM). Briefly, 1% carbopol with butylhydroxytoluene as antioxidant in a base of 1:1 parts of wheat and corn flour were mixed. Then, yellow-orange vegetable dye was added. Finally, doxycycline hyclate 10% was added at a rate of 10%. The mixture was mixed and then extruded at temperatures no greater than 30
• C, using ethyl-alcohol and cotton-seed oil as lubricants.
Aided by technical assistance, approximately 3 mL blood samples were obtained, by jugular puncture, from 10 broiler chickens per sampling time and per replicate in doxy-FOLA and doxy-ref groups, during 7 d at 6 am; 12 am and 8 pm (i.e., 1, 7 and 15 h after medicated feed was made available). Additionally, on day 1 and day 5, blood samplings were carried out more often at 6 am (1 h after medication) and at 8 am, 10 am, 12 noon, 4 pm, 8 pm, and 6 am next morning (that is, 1, 3, 5, 7, 11, 15 and 24 h after medicated feed was made available). Blood samples were also obtained prior medication. In doxy-IV groups (3 replicates with 100 broiler chickens per replicate), 5 different broiler chickens were sampled at each designated time: before the IV injection and at 0.5 1, 2, 3, 4, 6, 8, 12, and 24 h. Each broiler chicken was sampled only on one occasion. Samples were centrifuged directly at 1,000 × g for 5 min, serum harvested and stored at -20
• C until analyzed. Serum Dox concentrations were determined by highperformance liquid chromatography (HPLC) as described by Axisa et al. (2000) . A standard curve for doxycycline was constructed using antibiotic-free pooled serum samples collected from slaughtered, nonmedicated chickens. The intra-assay coefficient of variance was <1.9 and inter-assay error was <1.8. The analytic assay was linear over a range of concentrations from 0.1 to 100 μg/mL. Mean ± 1 SD recovery was 94 ± 2% (r = 0.97). Limit of detection was 0.07 μg/mL and limit of quantification was 0.1 μg/mL.
The pharmacokinetic model was determined by visual examination of the concentration-time curves and by application of Akaike information criterion. The peak concentration in plasma (Cmax) and the time to Cmax (Tmax) after oral administration were estimated by observed data from tabulated plasma concentrations. Other pharmacokinetic variables were calculated according to classical equations (Gibaldi and Perrier, 1982) . The mean pharmacokinetic variables were obtained by averaging the variables calculated for drug disposition after IV and oral drug administration. Oral bioavailability (F%) was calculated from the ratio of the areas under the plasma doxycycline concentration curve, after oral and IV administration. Relative bioavailability (Fr%) was derived from comparing AUC 0-24 from doxy-FOLA and doxy-ref groups. The time for which the serum drug levels remain above or equal to minimal inhibitory concentration (MIC) value was calculated as suggested by Turnidge (1998), as follows: (NCLS, 1993) . Six years of referrals were accounted for. Cationic-adjusted Müller-Hinton broth was used to prepare the bacterial inocula. The antimicrobial agent was serially diluted from 16 μg/mL to 0.062 μg/mL. E. coli (ATCC 25922) was used as control strain.
RESULTS
Mean ± 1 SD serum concentrations vs time profiles of doxycycline in broiler chickens after medication with either doxy-FOLA or doxy-ref are depicted in Figure 1 . Figure 2 shows the serum concentrations of doxycycline after its single IV administration, as well as serum concentrations of the antibacterial drug after dosing the drug as for doxy-FOLA and doxy-ref, on day 1. Table 1 shows pharmacokinetic data obtained for all 3 groups. Bioavailability values for the doxy-FOLA group were For the survey of 56 strains of pathogenic strains of Eschericha coli, a MIC50 was set at 2.0 μg/mL and MIC90 was obtained at 4.0 μg/mL. Hence, a very sensitive E. coli strain will be inhibited at 1.0 μg/mL. The time for which the serum doxycycline levels remain above or equal to MIC values and the AUC 0-24 /MIC ratios for doxy-FOLA and doxy-ref, considering MIC values obtained vs. E. coli, are also incorporated in Table 1. 3 levels of E coli susceptibility are depicted in Figures 1 and 2 . Considering the minimum MIC set, both oral preparations are likely to result in good clinical efficacy. However, this will not be the case if a MIC50 or a MIC90 E. coli pathogen is involved. In such cases, only chickens in the doxy-FOLA group would show appropriate AUC 0-24 /MIC and T > MIC ratios. Values for this latter variable, expressed as the percent of time at which serum concentrations remain above or equal to MIC between dosing intervals (24 h) (Turnidge, 1998) , are presented in Table 2 . From this table, it stands out that doxy-ref achieves higher values than 100% only on day 5 (136 to 220%, for MIC 4 and 1 μg/mL, respectively), while doxy-FOLA surpasses the same value of 100% since d 1 (314 to 507%, for MIC 4 and 1 μg/mL, respectively).
Broilers did not show any unusual sign of discomfort with either oral preparation of doxycycline during treatment or later. When chickens were slaughtered, neither macroscopic signs of GI tract damage nor irritation could be observed in either group.
DISCUSSION
The mean doxycycline serum concentration vs. time profile after the IV administration of the drug is shown in Figure 2 . It is best fitted to a 2-compartment open model, complying with previous results (Anadón et al., 1994; Soliman et al., 2015) , with a relatively rapid distribution half-life (T 1 2 α = 0.26 ± 0.01 h) and a slightly shorter elimination half-life in this study (T Explanation for the former difference may be due to methodological disparities, while in the latter, differences can also be due to a much higher dose administered and to the fact that serum concentrations of doxycycline were used as analysis matrix, in contrast to plasma concentrations. Notwithstanding the above, general data appears to follow the same pattern, but at higher doses.
Avian pathogenic E. coli strains are responsible for serious extra-intestinal diseases of poultry, causing high morbidity and mortality and leading to great economic losses (Russo and Johnson, 2000) . Pathogenic serovars of E. coli can cause a variety of diseases such as colisepticemia, egg peritonitis, yolk sac infection or omphalitis, coligranuloma, swollen head syndrome, complicated chronic respiratory disease, and other syndromes (Lister and Brown, 2008) . These infections are often associated with Mycoplasma spp. (Citti and Alain, 2013) . Doxycycline is active against these 2 microorganisms (Cunha et al., 2000) ; Sumano and Gutiérrez, 2009 ). However, susceptibility of individual strains involved, is likely to be variable (Cristina et al., 2010) . Hence, for PK/PD analysis, 3 arbitrary levels of bacterial sensitivity derived from our small survey are set in this trial for the E. coli: sensitive (1 μg/mL); less sensitive (2 μg/mL) and intermediate (4 μg/mL). Coincidently, these values as well as MIC value of the reference E. coli (ATCC 25922) (1.0 μg/mL) comply well with previous MICs for doxycycline and E. coli of human origin (Cunha et al., 1982; Cunha et al., 2000; Andrews, 2008) . Additionally, these 3 levels have also been utilized for pharmacodynamic studies in man (Cunha et al., 2000; Burch and Valks, 2002; Agwuh and MacGowan, 2006) . In our survey, MIC50 was obtained at 2.0 μg/mL, revealing a set of less susceptible bacteria and MIC90 was found at 4 μg/mL. If these 3 MIC levels of susceptibility of E. coli are hypothetically accepted then, only chicken receiving doxy-FOLA would be protected against the more resistant strains of E. coli (see Figure 1 and values listed in Table 1 ). Mycoplasma species are much more sensitive to doxycycline with MIC reported values in formal literature ranging from 0.006 to 0.2 μg/mL for Mycoplasma gallisepticum and from 0.125 to 0.7 μg/mL for Mycoplasma synoviae (Burch and Valks, 2002) .
Doxycycline is one of the most commonly used tetracyclines for the treatment of a wide variety of infectious diseases in poultry. It was introduced to poultry medicine decades before PK/PD considerations were incorporated into dose determination. Hence, the dosing of doxycycline has been mainly based on clinical observations. This is the first study of doxycycline in which a specific pharmaceutical preparation, intended for poultry, is used and in which PK/PD ratios are considered. By using doxy-FOLA in chickens (400 ppm), serum concentrations of the drug remain above the MIC value longer than 24 h, the customary dosing interval. The same value would be 11 h only in chicken receiving doxy-ref at the same dose. When these results are interpreted as percent of time at which doxycycline is in or above MIC values based on the equation proposed by Turnidge (1998) , chickens receiving doxy-ref achieve concentrations above MIC during the whole dosing interval (24 h) only on day 5 (136 to 220%, for MIC 4 and 1 μg/mL, respectively), while chickens receiving the same dose, but prepared as doxy-FOLA, surpasses the same values on day 1 (314 to 507%, for MIC 4 and 1 μg/mL, respectively). Similarly, when AUC 0-24 /MIC ratios are considered, doxy-, FOLA showed values that ranged from 56 to 298; i.e., much higher values than those obtained with doxy- ref (4.3 to 29) . These PK Table 2 . Time (expressed as percent) at which serum concentrations of doxycycline remain above or equal to minimal inhibitory concentration (MIC) in broiler chickens, on d 1 and 5, after dosing the antibacterial drug at 400 ppm, using two in-feed formulations of doxycycline, one intended for long acting (doxy-FOLA) and the other a commercially available reference premix (doxy-ref) . Calculations made as proposed by Turnidge (1998 This new preparation of doxy-FOLA contains carbopol, a polymeric matrix prone to slow the GI transit time, given its gastro-retentive properties (Uttam et al., 2016) . As claimed by Patent No. MX/a/2012/013222 and PCT/MX2013/000137, hardness of the pellet and the added carbopol allow the release of doxycycline into the GI tract and eventually into the duodenum loop, simulating a zero order kinetic drug release. In turn, this would program availability of doxycycline to the duodenal epithelium, thus enhancing bioavailability. Additionally, the yellow-orange color of the pellets appears to induce intended pecking of broiler chickens. In turn, this feature should ensure a homogeneous dosing of the flock. Further research is needed for confirmation.
Doxycycline is usually administered through drinking water when an outbreak of a susceptible disease is identified (Cristina et al., 2010) . Nevertheless, in commercial poultry houses in Latin-America, a small rise in daily mortality, together with a high lesion score found at necropsy, and the anticipated presence of Mycoplasma infection in the flock (Ismail and ElKattan, 2004) , is customary to link such findings with the beginning of an outbreak. In turn, this situation needs metaphilactic antibacterial intervention and infeed medication with doxycycline is established. The dose of doxycycline has been set at 400 ppm, mimicking the recommended dose of oxytetracycline for the control of chronic respiratory disease and air sac infection caused by Mycoplasma gallisepticum and Escherichia coli (Ismail and El-Kattan, 2004; Cristina et al., 2010) . Given the daily food intake of chickens during the first 3 weeks of age, a high dose in mg/kg is usually delivered i.e., 48 mg/kg in this trial; that is, more than twice the recommended 20 mg/kg given through drinking water (George et al., 1977; Goren et al., 1988; Anadón et al., 1994; Soliman et al., 2015) . Yet, this latter dose level appears to achieve serum concentrations below 1.0 μg/mL, 12 h after drug administration (Soliman et al., 2015) , a less than ideal concentration for doxycycline with a 24 h DI. In contrast and with better bioavailability of the administered dose of doxycycline with the doxy-FOLA preparation, high AUC/MIC ratios are obtained, a situation that may result in better clinical outcomes when border line susceptible E. coli pathogens are involved. Additionally, the T ≥ MIC ratio is more likely to be achieved with the doxy-FOLA preparation than with the reference in-feed medication. Although doxycycline is regarded as a time-dependent antibacterial drug, the index most likely associated with efficacy for tetracyclines in humans is AUC/MIC (Finch, 1997; Craig, 1998; Andes and Craig, 2002; Toutain and Lees, 2004) . For example, tigecycline seems to require a ratio of 30 for various Gram-positive pathogens in complicated skin and soft-tissue infections (Meagher et al., 2005; Meagher et al., 2007) . For doxycycline in dogs, Montecarlo simulations and target attainment analysis indicated a certainty of ≥90% for reaching a AUC/MIC ratio of >25 with a standard dosage of doxycycline (5 mg/kg of body weight every 12 h), and for strains with low MICs of ≤0.125 μg/mL (Maaland et al., 2013 ). Yet, no other specific AUC/MIC target has been published for doxycycline or other tetracyclines in veterinary medicine. In the present study, considering MIC values more than 10 fold higher than the ones described for dogs (1 to 4 μg/mL) and using a much higher dose of doxycycline (48 mg/kg), as in the preparation in study, intended for long-acting (FOLA), the ratios obtained for AUC/MIC were much higher i.e. 56 to 74 for d 1 and 5, when MIC = 4 μg/mL.
It is worth stating that broilers did not show any unusual sign of discomfort with either oral preparation of doxycycline during treatment or later. When chickens were slaughtered, neither macroscopic signs of GI tract damage nor irritation could be observed. Nevertheless, questions of drug-residue analysis must be fully characterized; i.e., doxycycline was detected in eggs for almost a month following cessation of the medication with conventional preparations of this antibacterial drug administered through the drinking water (Yoshimura et al., 1991) . Also the impact of this form of dosing doxycycline, bacterial resistance must be taken into consideration before this preparation is considered as suitable to treat commercial flocks.
